- Home
- NMI vs RCEL Comparison
NMI vs RCEL Comparison
Compare NMI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMI
- RCEL
- Stock Information
- Founded
- NMI 1988
- RCEL N/A
- Country
- NMI United States
- RCEL United States
- Employees
- NMI N/A
- RCEL N/A
- Industry
- NMI Trusts Except Educational Religious and Charitable
- RCEL Medical/Dental Instruments
- Sector
- NMI Finance
- RCEL Health Care
- Exchange
- NMI Nasdaq
- RCEL Nasdaq
- Market Cap
- NMI 103.8M
- RCEL 114.3M
- IPO Year
- NMI N/A
- RCEL N/A
- Fundamental
- Price
- NMI $10.02
- RCEL $3.82
- Analyst Decision
- NMI
- RCEL Buy
- Analyst Count
- NMI 0
- RCEL 5
- Target Price
- NMI N/A
- RCEL $11.75
- AVG Volume (30 Days)
- NMI 28.4K
- RCEL 202.3K
- Earning Date
- NMI 01-01-0001
- RCEL 11-06-2025
- Dividend Yield
- NMI 4.10%
- RCEL N/A
- EPS Growth
- NMI N/A
- RCEL N/A
- EPS
- NMI N/A
- RCEL N/A
- Revenue
- NMI N/A
- RCEL $72,401,000.00
- Revenue This Year
- NMI N/A
- RCEL $19.96
- Revenue Next Year
- NMI N/A
- RCEL $33.43
- P/E Ratio
- NMI N/A
- RCEL N/A
- Revenue Growth
- NMI N/A
- RCEL 20.59
- 52 Week Low
- NMI $8.30
- RCEL $3.35
- 52 Week High
- NMI $10.05
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- NMI 39.12
- RCEL 42.05
- Support Level
- NMI $9.99
- RCEL $3.51
- Resistance Level
- NMI $10.12
- RCEL $4.09
- Average True Range (ATR)
- NMI 0.07
- RCEL 0.27
- MACD
- NMI -0.01
- RCEL 0.06
- Stochastic Oscillator
- NMI 23.97
- RCEL 58.50
About NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.